Pancreatic Cancer Research

ResearcherMayo ClinicActive in the last 2 years

Daniel D. Billadeau

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-2296-9547; OpenAlex author ID A5080426319; NIH RePORTER profile ID 1895877. Sources: OpenAlex.

Their work

Papers
23 (first author 1, last author 6)
Trials
0
Grants
1
Labs led
1
Collaborators
77
Papers, trials and grants by year

2011: 1 paper · 2012: 1 paper · 2013: 1 paper · 2014: 3 papers · 2015: 2 papers · 2016: 3 papers · 2017: 1 paper · 2018: 1 grant · 2019: 2 papers · 2020: 4 papers · 2021: none · 2022: 1 paper · 2023: none · 2024: 1 paper · 2025: 2 papers · 2026: 1 paper

Papers 23

  1. Nuclear VAV1 increases GLI1-dependent transcription in pancreatic cancer cells. Co-author DOI 10.1016/j.jbc.2025.110988↗
  2. Fatty acid synthase (FASN) inhibition cooperates with BH3 mimetic drugs to overcome resistance to mitochondrial apoptosis in pancreatic cancer. Co-author DOI 10.1016/j.neo.2025.101143↗
  3. Genomic and Immune Landscape of Pancreatic Ductal Adenocarcinoma Associated with Germline Pathogenic Variants in ATM. Co-author DOI 10.1158/1078-0432.ccr-24-4120↗
  4. Microfluidic Organoid Cultures Derived from Pancreatic Cancer Biopsies for Personalized Testing of Chemotherapy and Immunotherapy. Co-author DOI 10.1002/advs.202303088↗
  5. Oncogenic Kras-Mediated Cytokine CCL15 Regulates Pancreatic Cancer Cell Migration and Invasion through ROS. Co-author DOI 10.3390/cancers14092153↗
  6. Glycogen synthase kinase-3β: a novel therapeutic target for pancreatic cancer. First author DOI 10.1080/14728222.2020.1743681↗
  7. An FGFR/AKT/SOX2 Signaling Axis Controls Pancreatic Cancer Stemness. Co-author DOI 10.3389/fcell.2020.00287↗
  8. Corrigendum: An FGFR/AKT/SOX2 Signaling Axis Controls Pancreatic Cancer Stemness. Co-author DOI 10.3389/fcell.2020.594589↗
  9. The WW domains dictate isoform-specific regulation of YAP1 stability and pancreatic cancer cell malignancy. Co-author DOI 10.7150/thno.42795↗
  10. Glycogen Synthase Kinase-3 Inhibition Sensitizes Pancreatic Cancer Cells to Chemotherapy by Abrogating the TopBP1/ATR-Mediated DNA Damage Response. Last author DOI 10.1158/1078-0432.ccr-19-0799↗
  11. Glypican-1 and glycoprotein 2 bearing extracellular vesicles do not discern pancreatic cancer from benign pancreatic diseases. Co-author DOI 10.18632/oncotarget.26620↗
  12. Fructose-1,6-bisphosphatase Inhibits ERK Activation and Bypasses Gemcitabine Resistance in Pancreatic Cancer by Blocking IQGAP1-MAPK Interaction. Co-author DOI 10.1158/0008-5472.can-16-3143↗
  13. NFATc4 Regulates Sox9 Gene Expression in Acinar Cell Plasticity and Pancreatic Cancer Initiation. Co-author DOI 10.1155/2016/5272498↗
  14. SIRT1-Activating Compounds (STAC) Negatively Regulate Pancreatic Cancer Cell Growth and Viability Through a SIRT1 Lysosomal-Dependent Pathway. Co-author DOI 10.1158/1078-0432.ccr-15-1760↗
  15. GSK-3β Governs Inflammation-Induced NFATc2 Signaling Hubs to Promote Pancreatic Cancer Progression. Co-author DOI 10.1158/1535-7163.mct-15-0309↗
  16. Nuclear FAM21 participates in NF-κB-dependent gene regulation in pancreatic cancer cells. Last author DOI 10.1242/jcs.161513↗
  17. Antithetical NFATc1-Sox2 and p53-miR200 signaling networks govern pancreatic cancer cell plasticity. Co-author DOI 10.15252/embj.201489574↗
  18. Differential activity of GSK-3 isoforms regulates NF-κB and TRAIL- or TNFα induced apoptosis in pancreatic cancer cells. Last author DOI 10.1038/cddis.2014.102↗
  19. Differential activity of GSK-3 isoforms regulates NF-κB and TRAIL- or TNFα induced apoptosis in pancreatic cancer cells Last author DOI 10.1038/cddis.2014.341↗
  20. Inflammation-induced NFATc1-STAT3 transcription complex promotes pancreatic cancer initiation by KrasG12D. Co-author DOI 10.1158/2159-8290.cd-13-0593↗
  21. SOX2 promotes dedifferentiation and imparts stem cell-like features to pancreatic cancer cells. Last author DOI 10.1038/oncsis.2013.23↗
  22. Restricted heterochromatin formation links NFATc2 repressor activity with growth promotion in pancreatic cancer. Co-author DOI 10.1053/j.gastro.2011.11.001↗
  23. Mutant K-Ras increases GSK-3β gene expression via an ETS-p300 transcriptional complex in pancreatic cancer. Last author DOI 10.1038/onc.2011.90↗

Grants 1

  1. Administrative Core P50CA102701↗

Closest collaborators

The 25 strongest of 77 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jin‐San Zhang · 11 shared papers, 2012–2020 · strength 0.67
  2. Martín E. Fernández-Zapico · 4 shared papers, 1 shared grant, 2011–2026 · strength 0.53
  3. Robert R. McWilliams · 2 shared papers, 2025 · strength 0.41
  4. Li Ding · 3 shared papers, 2019–2020 · strength 0.41
  5. Fergus Joseph Couch · 2 shared papers, 1 shared grant, 2011–2025 · strength 0.38
  6. Alexander Otto König · 8 shared papers, 2011–2016 · strength 0.31
  7. Brooke R Tader · 1 shared paper, 2026 · strength 0.29
  8. Kayla C. LaRue-Nolan · 1 shared paper, 2026 · strength 0.29
  9. Volker Ellenrieder · 7 shared papers, 2012–2016 · strength 0.28
  10. Zhenkun Lou · 3 shared papers, 2020 · strength 0.28
  11. Meiyu Quan · 3 shared papers, 2020 · strength 0.28
  12. Qiang Guo · 3 shared papers, 2020 · strength 0.28
  13. Thomas C. Smyrk · 3 shared papers, 1 shared grant, 2013–2018 · strength 0.25
  14. Geou‐Yarh Liou · 2 shared papers, 2016–2022 · strength 0.23
  15. Debabrata Mukhopadhyay · 1 shared paper, 1 shared grant, 2018–2019 · strength 0.23
  16. Travis Vander Steen · 1 shared paper, 2025 · strength 0.22
  17. Ruth Lupu · 1 shared paper, 2025 · strength 0.22
  18. Eduardo N Chini · 1 shared paper, 1 shared grant, 2016–2018 · strength 0.21
  19. Li Ding · 1 shared paper, 2025 · strength 0.20
  20. Chunling Hu · 1 shared paper, 2025 · strength 0.20
  21. Rondell Patrell Graham · 1 shared paper, 2025 · strength 0.20
  22. Siddhartha Yadav · 1 shared paper, 2025 · strength 0.20
  23. Shounak Majumder · 1 shared paper, 2025 · strength 0.20
  24. Jiayu Liu · 2 shared papers, 2020 · strength 0.19
  25. Jeffrey S. Miller · 1 shared paper, 2024 · strength 0.18

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.